Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nogapendekin alfa inbakicept + PD-L1 t-haNK
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
bevacizumab + nogapendekin alfa inbakicept + PD-L1 t-haNK is a combination immunotherapy regimen under development by ImmunityBio for the treatment of recurrent or progressive glioblastoma (GBM). The regimen, evaluated in the QUILT-3.078 clinical trial, combines three distinct therapeutic modalities: bevacizumab, an anti-VEGF monoclonal antibody that inhibits angiogenesis; nogapendekin alfa inbakicept (N-803), an IL-15 superagonist fusion protein that activates and expands natural killer (NK) and T cells; and PD-L1 t-haNK cells, which are off-the-shelf, high-affinity NK cells engineered to target PD-L1-expressing tumor cells. This tri-modal approach is designed to enhance immune infiltration and overcome the highly immunosuppressive environment characteristic of glioblastoma.
- Other names
- bevacizumab + N-803 + PD-L1 t-haNKbevacizumab + NAI + PD-L1 t-haNK
02
Targets
VEGFA (Vascular endothelial growth factor A)IL-2/IL-15Rβγ (Interleukin-2/15 receptor subunit beta/common subunit gamma signaling complex)CD274 (Programmed cell death protein 1 ligand 1)Interleukin-15 receptor subunit alpha sushi domain
Beyond the preview
Go deeper on bevacizumab + nogapendekin alfa inbakicept + PD-L1 t-haNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nogapendekin alfa inbakicept + PD-L1 t-haNK.